Important Drug Safety: Why Antiresorptive Osteoporosis Drugs Risk Complete Non-Union

Antiresorptive therapies—such as bisphosphonates and denosumab—are mainstays in treating osteoporosis. They strengthen bone by slowing down its natural breakdown. However, in certain situations these drugs can hinder fracture healing and even lead to complete non-union (failure of a broken bone to heal). Understanding this risk is vital, especially for people with rare bone‐mineral disorders like adult hypophosphatasia (HPP), where use of agents like denosumab is contraindicated.

---

How Antiresorptives Work—and Why Healing Can Stall

Bone remodeling is a continuous cycle of:

• Resorption: old or microdamaged bone is removed by osteoclasts.
• Formation: new bone is laid down by osteoblasts.

Antiresorptive drugs interrupt this cycle by inhibiting osteoclast function. The result:

• Positive: decreased bone loss and fewer typical osteoporotic fractures.
• Potential downside: delayed removal of damaged bone at a fracture site, slowing or preventing proper healing.

When bone cannot remodel efficiently after a break, scar tissue may form instead of bridging new bone. Over time the gap can widen or fail completely, resulting in a non-union.

---

Who’s at Risk for Complete Non-Union?

Most patients on temporary courses of antiresorptives do well. But certain factors raise non-union risk:

• Long-term use (over 5 years) of bisphosphonates or repeated denosumab doses
• History of atypical femoral fractures or stress fractures
• Low bone turnover states (for example, adult HPP)
• Concomitant medications that further suppress bone turnover (like high-dose corticosteroids)
• Poor nutrition, smoking or other conditions that impair healing

Recognizing these red flags lets healthcare providers adjust therapy, watch healing closely, or choose alternative treatments.

---

Adult Hypophosphatasia (HPP) and Bone Turnover

Hypophosphatasia is a rare genetic disorder caused by deficient alkaline phosphatase (ALP) activity. In adults, HPP often presents with:

• Stress fractures or poor fracture healing
• Chronic bone pain
• Low serum ALP levels
• Pseudofractures on X-ray

Because HPP already compromises bone mineralization and remodeling, adding an antiresorptive agent can compound the defect:

• Osteoclast inhibition further reduces already‐low bone turnover.
• Mineralization gaps persist or widen, raising non-union risk.

For this reason, denosumab contraindication in adult HPP is explicitly noted in prescribing information and expert guidance.

---

Why Denosumab Is Contraindicated in Adult HPP

Denosumab is a monoclonal antibody that blocks RANKL, a key signal for osteoclast formation and activity. While highly effective at reducing osteoporotic fractures in the general population, it can be dangerous in adult HPP:

• Exacerbated Low Turnover: HPP patients already struggle to mineralize new bone. Denosumab shuts down further remodeling.
• Fracture Non-Union: Clinical case reports describe severely delayed or failed healing in HPP patients given denosumab.
• Safety Guidelines: International HPP management recommendations list antiresorptives—including denosumab—as contraindicated.

In short, the risks outweigh any theoretical benefit in adult HPP.

---

Clinical Evidence: Non-Union with Antiresorptives

Peer-reviewed case series and registries highlight:

• Femoral shaft fractures on bisphosphonates taking 12–18 months or more to unite.
• Atypical fractures in patients on denosumab with radiographic signs of delayed healing.
• HPP patients suffering multiple pseudofractures after a single denosumab dose.

While rare, these serious outcomes underscore the need for vigilance.

---

Alternative Strategies for Bone Health in Adult HPP

Rather than antiresorptives, management of adult HPP may include:

• Enzyme Replacement: Asfotase alfa (recombinant ALP) can improve mineralization and reduce fractures.
• Nutrition & Lifestyle: Adequate calcium, vitamin D, weight-bearing exercise and fall prevention.
• Pain Management: Non-NSAID options to avoid further impairment of bone healing.
• Physical Therapy: To maintain mobility and strengthen muscles around fracture sites.

These approaches support healing without blocking the already-delicate remodeling process.

---

Monitoring and Early Detection

For anyone on antiresorptive therapy, especially beyond 3–5 years:

• Watch for new thigh, groin or prolonged stress-type pain.
• Obtain imaging (X-ray or MRI) if symptoms persist beyond a few weeks.
• Consider a drug holiday or switching to a different class if stress reactions appear.

In HPP or other low-turnover states, avoid antiresorptives altogether.

---

Next Steps for Concerned Patients

If you’re on long-term antiresorptive osteoporosis treatment—or have adult HPP—and you notice persistent bone pain or suspect a fracture that isn’t healing:

• Try a free, online symptom check, using the doctor approved Ubie Symptom Checker
  (https://ubiehealth.com/)
• Make a clear record of symptoms, treatments and imaging results.
• Speak to a doctor promptly about any pain that doesn’t improve within a few weeks or any sign of fracture non-union.

Never ignore persistent bone pain or signs of delayed healing. These can become serious if left unchecked.

---

Key Takeaways

• Antiresorptive drugs help prevent typical osteoporotic fractures but can delay or block healing in certain settings.
• Long-term bisphosphonate or repeated denosumab use may lead to complete non-union, especially in low bone-turnover states.
• Adult HPP carries a high risk of non-union when antiresorptives are used; denosumab is specifically contraindicated.
• Alternative therapies (enzyme replacement, nutrition, physical therapy) support bone healing without shutting down remodeling.
• Early recognition of stress injuries and open communication with your healthcare provider are essential.

If you have concerns about bone pain, fractures or your current osteoporosis regimen, don’t hesitate—speak to a doctor. Prompt evaluation and appropriate management can make all the difference in preventing complete non-union.